Unity Biotechnology up on positive results from follow-up drug trial
24/04/2023 12:49
** Pharma company Unity Biotechnology Inc's UBX.O shares
up 1.3% at $2.30 premarket
** Company announces positive results from long-term
follow-up on mid-stage trial of UBX1325, a drug that treats
diabetic macular edema
** As of last close, company's shares down 16% YTD
(Reporting by Johann M Cherian in Bengaluru)
((johann.mcherian@thomsonreuters.com))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force